Awakn Life Sciences Initiates Investigative Study Of Novel Formulation Of (S)-Ketamine To Assess Dissociative Effect
Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II TORONTO, CANADA, January 24, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”),…